A Phase I/II Trial of AN-152 (AEZS-108) in Castration- and Taxane-Resistant Prostate Cancer.

Trial Profile

A Phase I/II Trial of AN-152 (AEZS-108) in Castration- and Taxane-Resistant Prostate Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Zoptarelin doxorubicin (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 18 Feb 2017 Results (n=25) assessing clinical benefit of zoptarelin doxorubicin in castration- and taxane-resistant prostate cancer patients from phase II portion of the study, presented at the 2017 Genitourinary Cancers Symposium.
    • 14 Feb 2017 Results published in an Aeterna Zentaris media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top